Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27298134 | 1.00 | CA1 (0.33) | CA1CA2KDM1AKCNH2KDM1B | |
| SCHEMBL27969185 | 0.80 | KDM1A (0.35) | KDM1AKCNH2KDM1BKIF11 | |
| SCHEMBL18322551 | 0.79 | PTGER4 (0.38) | KDM1AKCNH2KDM1BPTGER4 | |
| SCHEMBL932455 | 0.78 | PRKCI (0.33) | PRKCI | |
| SCHEMBL29860588 | 0.78 | PRKCI (0.33) | PRKCI | |
| SCHEMBL30236233 | 0.77 | PRKCI (0.32) | PRKCIPTGER4 | |
| SCHEMBL16831105 | 0.77 | PRKCI (0.32) | PRKCIPTGER4 | |
| SCHEMBL16831157 | 0.75 | PTGER4 (0.53) | PRKCIPTGER4 | |
| SCHEMBL30216060 | 0.75 | KDM1A (0.38) | CA1CA2KDM1AKCNH2KDM1B | |
| SCHEMBL1494553 | 0.75 | KDM1A (0.38) | CA1CA2KDM1AKCNH2KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042747-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ALIVEXIS, INC. (JP) | 2026-02-12 | — | — | US | disclosed |
| US-20250326770-A1 | BENZOTRIAZOLE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-10-23 | — | — | US | disclosed |
| US-12378260-B2 | Benzotriazole compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-08-05 | — | — | US | disclosed |
| EP-4587438-A1 | BICYCLIC COMPOUNDS AS CDK INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-07-23 | — | — | EP | disclosed |
| EP-4565575-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Alivexis, Inc. (JP) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025096771-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-119894890-A | Bicyclic compounds as CDK inhibitors | 百济神州(苏州)生物科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119866333-A | KIT inhibitors, compounds, pharmaceutical compositions, and methods of use thereof | 亚力维克希斯股份有限公司 | 2025-04-22 | — | — | CN | disclosed |
| US-20250092064-A1 | BENZOTRIAZOLE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-20 | — | — | US | disclosed |
| WO-2025052129-A1 | PYRIDINE DERIVATIVES WHICH ACT AS INHIBITORS OF MPTP. | NRG THERAPEUTICS LTD (GB) | 2025-03-13 | — | — | WO | disclosed |
| EP-4509504-A1 | BENZOTRIAZOLE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2025-02-19 | — | — | EP | disclosed |
| CN-119173511-A | Benzotriazole compounds | 第一三共株式会社 | 2024-12-20 | — | — | CN | disclosed |
| WO-2024117179-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ALIVEXIS, INC. (JP) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024029489-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MODULUS DISCOVERY, INC. (JP) | 2024-02-08 | — | — | WO | disclosed |
| WO-2023210741-A1 | BENZOTRIAZOLE COMPOUND | 第一三共株式会社 | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092064-A1 | BENZOTRIAZOLE COMPOUND | NFE2L2, BPTF, KEAP1 | CA1 4771/4885CA2 3243/4885KDM1A 2672/4885 |
| US-12378260-B2 | Benzotriazole compound | NFE2L2, BPTF, KEAP1 | CA1 4771/4885CA2 3243/4885KDM1A 2672/4885 |
| US-20250326770-A1 | BENZOTRIAZOLE COMPOUND | KEAP1, NFE2L2, TXNRD2 | CA1 4804/4885CA2 3963/4885KDM1A 2307/4885 |
| US-20260042747-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KIT, LTK, HRH3 | CA1 748/4885CA2 380/4885KDM1A 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.